Trial · NCT03439345
Results by group56
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 56
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Fenofibrate 145 mg | 131 | Participants | ||
| Number of Participants With Progression to Referable Diabetic Retinopathy or Maculopathy, or Treatment | Placebo Oral Tablet | 168 | Participants | ||
| Number of Participants With the Individual Component of the Composite Primary Outcome: Development of Referable Diabetic Retinopathy or Maculopathy | Fenofibrate 145 mg | 130 | Participants | ||
| Number of Participants With the Individual Component of the Composite Primary Outcome: Development of Referable Diabetic Retinopathy or Maculopathy | Placebo Oral Tablet | 168 | Participants | ||
| Number of Participants With the Individual Component of Composite Primary Outcome: Treatment for Diabetic Retinopathy or Maculopathy | Fenofibrate 145 mg | 17 | Participants | ||
| Number of Participants With the Individual Component of Composite Primary Outcome: Treatment for Diabetic Retinopathy or Maculopathy | Placebo Oral Tablet | 28 | Participants | ||
| Number of Participants With Any Progression of Diabetic Retinopathy or Maculopathy Across the NHS Scotland Retinopathy Grading Scale | Fenofibrate 145 mg | 185 | Participants | ||
| Number of Participants With Any Progression of Diabetic Retinopathy or Maculopathy Across the NHS Scotland Retinopathy Grading Scale | Placebo Oral Tablet | 231 | Participants | ||
| Number of Participants With Referable Maculopathy (Exudates or Blot Haemorrhages Within One Disc Diameter of the Fovea) | Fenofibrate 145 mg | 107 | Participants | ||
| Number of Participants With Referable Maculopathy (Exudates or Blot Haemorrhages Within One Disc Diameter of the Fovea) | Placebo Oral Tablet | 149 | Participants | ||
| Number of Participants With The Development of Macular Oedema | Fenofibrate 145 mg | 22 | Participants | ||
| Number of Participants With The Development of Macular Oedema | Placebo Oral Tablet | 43 | Participants | ||
| Visual Acuity | Fenofibrate 145 mg | 0.06 | 95% Confidence Interval 0.05 to 0.07 | LogMAR | |
| Visual Acuity | Placebo Oral Tablet | 0.05 | 95% Confidence Interval 0.05 to 0.06 | LogMAR | |
| Visual Function, Based on the National Eye Institute Visual Functioning Questionnaire 25 (VFQ-25). | Fenofibrate 145 mg | 90 | 95% Confidence Interval 89 to 91 | score on a scale | |
| Visual Function, Based on the National Eye Institute Visual Functioning Questionnaire 25 (VFQ-25). | Placebo Oral Tablet | 89 | 95% Confidence Interval 89 to 90 | score on a scale | |
| Quality of Life, Based on the EQ-5D Index Score | Fenofibrate 145 mg | 0.75 | 95% Confidence Interval 0.73 to 0.76 | score on a scale | |
| Quality of Life, Based on the EQ-5D Index Score | Placebo Oral Tablet | 0.75 | 95% Confidence Interval 0.74 to 0.76 | score on a scale | |
| Quality of Life, Based on the EQ-5D Visual Analogue Scale. | Fenofibrate 145 mg | 75 | 95% Confidence Interval 74 to 76 | score on a scale | |
| Quality of Life, Based on the EQ-5D Visual Analogue Scale. | Placebo Oral Tablet | 76 | 95% Confidence Interval 75 to 77 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03439345/results